Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study
Open Access
- 27 July 2020
- preprint content
- other
- Published by Cold Spring Harbor Laboratory
Abstract
Objectives To investigate the relation of severe COVID-19 to prior drug prescribing. Design Matched case-control study (REACT-SCOT) based on record linkage to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days. Setting Scottish population. Main outcome measure Severe COVID-19, defined by entry to critical care or fatal outcome. Participants All 4272 cases of severe COVID-19 in Scotland since the start of the epidemic, with 36948 controls matched for age, sex and primary care practice. Results Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in care homes, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.7, 13.2), and was not accounted for by treatment of conditions designated as conferring increased risk. Of 17 drug classes postulated at the start of the epidemic to be “medications compromising COVID”, all were associated with increased risk of severe COVID-19. The largest effect was for antipsychotic agents: rate ratio 4.14 (3.39, 5.07). Other drug classes with large effects included proton pump inhibitors (rate rato 2.19 (1.70, 2.80) for >= 2 defined daily doses/day), opioids (3.62 (2.65, 4.94) for >= 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates, and were stronger with recent than with non-recent exposure. Conclusions Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression or dyskinesia, have anticholinergic effects or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Although the evidence for causality is not conclusive, these results support existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy as a potential means of reducing COVID-19 risk. Registration ENCEPP number EUPAS35558 What is already known on this topic Two previous studies have examined the relationship of severe COVID-19 to drugs for the cardiovascular system. This is the first systematic study of the relationship of severe COVID-19 to prior drug prescribing. What this study adds Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression or dyskinesia, have anticholinergic effects or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. These results support earlier warnings that these drug classes that these drugs might increase susceptibility to COVID-19, and reinforce existing guidance on reducing overprescribing of these drug classes.Keywords
This publication has 15 references indexed in Scilit:
- Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19New England Journal of Medicine, 2020
- COVID-19 and its implications for thrombosis and anticoagulationBlood, 2020
- Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): a population-based case-control studyPublished by Cold Spring Harbor Laboratory ,2020
- COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquineJournal of Clinical Epidemiology, 2020
- Enteric involvement in hospitalised patients with COVID-19 outside WuhanThe Lancet Gastroenterology & Hepatology, 2020
- National Therapeutic Indicators in Scotland and Financial IncentivesInternational Journal of Population Data Science, 2019
- Association of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIVJAMA Internal Medicine, 2019
- Association between polypharmacy and death: A systematic review and meta-analysisJournal of the American Pharmacists Association, 2017
- Data Resource Profile: The Scottish National Prescribing Information System (PIS)International Journal of Epidemiology, 2016
- Cardiovascular polypharmacy is not associated with unplanned hospitalisation: evidence from a retrospective cohort studyBMC Family Practice, 2014